Honeywell has begun large scale manufacturing of Solstice Air HFO-1234ze(E), a low global-warming-potential (GWP) MDI propellant, at a facility located in Baton Rouge, LA, USA, the company said. In February 2022, AstraZeneca announced that it would reformulate Breztri budesonide/ glycopyrronium/ formoterol fumarate using Solstice Air as part of a partnership with Honeywell and that it planned to develop other MDIs using HFO-1234ze as well.
At RDD 2022, Honeywell reported some Solstice Air data as part of a session on lower-GWP propellants and exhibited at the meeting for the first time. Over the past year, a number of CDMOs and device companies have added services for the transition to low-GWP propellants such as HFO-1234ze and HFA 152a, including H&T Presspart, Recipharm, and Kindeva Drug Delivery.
Honeywell Advance Materials President Ken West said, “Honeywell is dedicated to supporting our customers’ environmental transformations with ready-now solutions. The opening of this plant in Baton Rouge is Honeywell’s first site to produce medical grade propellant and our continued work with AstraZeneca offers a critical moment to highlight how Honeywell’s Solstice technology plays an important role in helping the pharmaceutical industry meet its sustainability goals while supporting essential care for respiratory patients worldwide.”
AstraZeneca Senior VP, Global Respiratory & Immunology, Pablo Panella commented, “AstraZeneca’s commercial partnership with Honeywell is an excellent example of a true commitment to advancing healthcare innovation to improve outcomes both for patients and the planet. Through close collaboration and extensive knowledge sharing between our two companies, we are committed to bringing the next generation of inhaled medicines with near-zero GWP propellant to patients. Honeywell’s ability to escalate the production of Solstice Air at their new manufacturing site will help enable us to move quickly on this ambition once regulatory approval is achieved.”
Read the Honeywell press release.
